Status:
COMPLETED
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Lead Sponsor:
Eurnekian Public Hospital
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease. It is estimat...
Detailed Description
CONTAGION COURSE Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this diseas...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Not younger than 18 years of either sex
- Health personnel from the Dr. Alberto Eurnekian Interzonal University Hospital
- No COVID-19 related symptoms
- Able to understand and give written informed consent
- Exclusion criteria
- Known hypersensitivity or allergy to any component of the product under evaluation
- Age under 18 years
- Use of immunosuppressants (including systemic corticosteroids) in the past 30 days.
- Pregnant or nursing.
- Patients with other acute infectious diseases.
- Patients with autoimmune disease and / or decompensated chronic diseases.
- Unable to fulfill the administrative tasks proposed by the study.
- Infection with SARSCoV-2 confirmed by PCR or rapid test authorized by ANMAT.
Exclusion
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 10 2020
Estimated Enrollment :
229 Patients enrolled
Trial Details
Trial ID
NCT04425850
Start Date
June 1 2020
End Date
August 10 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Eurnekian
Buenos Aires, Argentina, 1802